News | February 10, 2025
Wockhardt posts Q3 net profit at Rs. 20 Cr
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Plans underway to expand screening capacity by 50% for greater accessibility
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Subscribe To Our Newsletter & Stay Updated
